Swedish Orphan Biovitrum AB (SOBI)

Sobi is a leading integrated biopharmaceutical company dedicated to bringing innovative therapies and services to improve the lives of rare disease patients and their families.

Our research and product portfolio is primarily focused on haemophilia, inflammation and genetic and metabolic diseases.
We market and make available across Europe, the Middle East, North Africa and Russia a portfolio of specialty and rare disease products for partner companies.
We have world-class capabilities in protein biochemistry and biologics manufacturing development - validated by leading industry partners.
We manufacture the drug substance for the haemophilia treatment ReFacto AF/Xyntha® for the global market.